Geographic visualization research has focused on a variety of techniques to represent and explore spatiotemporal data. The goal of those techniques is to enable users to explore events and interactions over space and time in order to facilitate the discovery of patterns, anomalies and relationships within the data. However, it is difficult to extract and visualize data flow patterns over time for non-directional statistical data without trajectory information. In this work, we develop a novel flow analysis technique to extract, represent, and analyze flow maps of non-directional spatiotemporal data unaccompanied by trajectory information. We estimate a continuous distribution of these events over space and time, and extract flow fields for spatial and temporal changes utilizing a gravity model. Then, we visualize the spatiotemporal patterns in the data by employing flow visualization techniques. The user is presented with temporal trends of geo-referenced discrete events on a map. As such, overall spatiotemporal data flow patterns help users analyze geo-referenced temporal events, such as disease outbreaks, crime patterns, etc. To validate our model, we discard the trajectory information in an origin-destination dataset and apply our technique to the data and compare the derived trajectories and the original. Finally, we present spatiotemporal trend analysis for statistical datasets including twitter data, maritime search and rescue events, and syndromic surveillance.

We evaluated the dose-responsiveness, efficacy, and safety of low-dose triple antihypertensive combination therapies in patients with mild-to-moderate hypertension. Patients and Methods: After a 1 to 2-week placebo run-in period, 248 patients were randomized to the half-dose triple combination (amlodipine 2.5 mg + losartan 25 mg + chlorthalidone 6.25 mg), third-dose triple combination (amlodipine 1.67 mg + losartan 16.67 mg + chlorthalidone 4.17 mg), quarter-dose triple combination (amlodipine 1.25 mg + losartan 12.5 mg + chlorthalidone 3.13mg), amlodipine 10mg, amlodipine 5mg, losartan 100mg, and placebo groups for 8 weeks. The primary outcome was the mean change in systolic blood pressure (SBP) from baseline to week 8. Results: The placebo-corrected SBP reductions of the half-dose, third-dose, quarter-dose combination, amlodipine 10 mg, amlodipine 5 mg and losartan 100 mg treatments were −17.2, −19.5, −14.9, −18.5, −11.3 and −9.9 mmHg, respectively. The BP control and response rates were significantly higher in the half-dose, third-dose, and quarter-dose combination groups than in the placebo group (all p < 0.01). Despite no intergroup differences in study drug-related adverse events, ankle circumference increased significantly in the amlodipine group compared to those in the combination treatment groups. The quarter-dose combination, amlodipine 5 mg, and losartan 100 mg groups showed similar SBP reduction and BP response rates. The SBP reduction and BP response rate in the third-dose and halfdose combination groups were not significantly different from those in the amlodipine 10 mg group but superior to those in the losartan 100 mg group. Conclusion: Low-dose triple combination therapies could be effective as antihypertensive therapies. Trial Registration: ClinicalTrials.gov identifier NCT03897868.

Attenuated plaque was more common in ACS patients with STEMI than NSTEMI. Attenuated plaque in ACS patients was associated with a higher C-reactive protein level, more severe and complex lesion morphology, reduced coronary blood flow before PCI, and especially no-reflow after PCI.

No abstract

No abstract